Aitini E, Cavazzini G, Pasquini E, Rabbi C, Colombo F, Cantore M, Fattori P P, Pari F, Bertuzzi A, Smerieri F
Department of Medical Oncology, Ospedale Carlo Poma, Mantova, Italy.
Acta Oncol. 1994;33(2):191-4. doi: 10.3109/02841869409098404.
Thirty-three patients with microscopically verified primary or metastatic malignant pleural effusion were studied: 7 had malignant mesothelioma and 26 metastatic pleural disease. The treatment was based on biochemical and clinical studies which show a synergy between cytosine-arabinoside (Ara-C) and cisplatin. These drugs were instilled in the pleural cavity at the dose of 100 mg for Ara-C and 100 mg/m2 for cisplatin. The cavity was drained after 4 h. If it was possible, the treatment was repeated weekly for 3 times and, after a 6-week rest, it could be started again with the same schedule. The overall response rate (complete plus partial remissions) was 74%. Toxicity was mild or moderate. We conclude that the combination of Ara-C and cisplatin is well tolerated and produces a high response rate in the treatment of malignant pleural effusions.
对33例经显微镜检查证实为原发性或转移性恶性胸腔积液的患者进行了研究：7例患有恶性间皮瘤，26例患有转移性胸膜疾病。治疗基于生化和临床研究，这些研究表明阿糖胞苷（Ara-C）和顺铂之间存在协同作用。这些药物以阿糖胞苷100mg和顺铂100mg/m²的剂量注入胸腔。4小时后排出胸腔积液。如果可能，治疗每周重复1次，共3次，休息6周后，可按相同方案再次开始治疗。总缓解率（完全缓解加部分缓解）为74%。毒性为轻度或中度。我们得出结论，阿糖胞苷和顺铂联合使用耐受性良好，在治疗恶性胸腔积液中产生高缓解率。
